Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lonafarnib with Paclitaxel/Carboplatin in First-Line Ovarian Cancer
NCT00281515Phase 2Completed
- Sponsor
- AGO Study Group
- Start
- Jan 2006
- Primary completion
- Dec 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of lonafarnib in epithelial ovarian cancer (EOC), fallopian tube cancer (PFTC) and primary peritoneal carcinoma (PPC) (2 arms), sponsored by AGO Study Group. Primary endpoint: Progression-free survival. Started Jan 2006; status: completed.
02
Drugs
lonafarnib
03
Conditions
epithelial ovarian cancer (EOC)fallopian tube cancer (PFTC)primary peritoneal carcinoma (PPC)
Beyond the preview
Go deeper on NCT00281515.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00281515.